Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Percheron Therapeutics ( (AU:PER) ).
Percheron Therapeutics Limited announced a change in the director’s interest, with Director James Garner acquiring an additional 2,500,000 fully paid ordinary shares, increasing his holdings to 52,500,000 shares. This acquisition, conducted through an on-market purchase valued at $24,960, reflects a strategic move to strengthen the director’s stake in the company, potentially signaling confidence in the company’s future prospects and stability in the biotechnology market.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutic solutions. The company is involved in the research and production of innovative treatments, aiming to address unmet medical needs in the healthcare sector.
Average Trading Volume: 2,513,005
Technical Sentiment Signal: Sell
Current Market Cap: A$9.79M
See more insights into PER stock on TipRanks’ Stock Analysis page.